AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
|Articles|November 1, 2001
Supplements and Featured Publications
- New Directions in the Treatment and Prevention of Deep Vein Thrombosis
- Volume 7
- Issue 17 Suppl
Participating Faculty
Advertisement
Articles in this issue
about 25 years ago
Introductionabout 25 years ago
Treatment of Deep Vein Thrombosis Using Low-Molecular-Weight Heparinsabout 25 years ago
Prophylaxis Strategies for Patients with Acute Venous Thromboembolismabout 25 years ago
Interviewabout 25 years ago
Continuing Medical Education Quizabout 25 years ago
Literature ReviewAdvertisement
Related to this article
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
4
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
5